A Japanese company has announced that it is starting a clinical trial for an exon 53 skipping morpholino. I don't have any more details beyond this notice, but would think it's highly unlikely that any out-of-country participants would be considered just based on how the Japanese regulatory system works. (both Sarepta and Prosensa are also in the preclinical stages for an exon 53 skipping drug) P…